Patents Assigned to Nuvalent, Inc.
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 12275742
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: April 15, 2025
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 12054498
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: August 6, 2024
    Assignee: NUVALENT, INC.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
    Patent number: 12043626
    Abstract: Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 23, 2024
    Assignee: Nuvalent, Inc.
    Inventors: Sibao Chen, Christopher G. F. Cooper, Baudouin Gerard, Joshua Courtney Horan, Jason T. Kropp, Benjamin Stephen Lane, David James Pearson
  • Amino-substituted heteroaryls for treating cancers with EGFR mutations
    Patent number: 12037346
    Abstract: Disclosed are amino-substituted heteroaromatic compounds such as a compound of Formula (I): pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: July 16, 2024
    Assignee: Nuvalent, Inc.
    Inventors: Kristin Lynne Andrews, Baudouin Gerard, Joshua Courtney Horan, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Yuting Sun, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11667649
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 6, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11542278
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 3, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul